UNLOCKING THE POTENTIAL OF
The overall results of the SPINRAZA clinical studies support the early initiation of treatment
In some cases, genetic testing is used to diagnose SMA in infants before symptoms develop. At day 183 of an open-label* study, some presymptomatic infants treated with SPINRAZA achieved age-appropriate milestones.
*Open-label study=a type of clinical study in which both patients and researchers know what treatment is being given.
Achievement of HINE Section 2 motor milestones
At the time of the interim analysis, the open-label study had enrolled 17 infants. At day 183, motor milestones were assessed for those who had reached a suitable age for measurement.
It’s the joy of simple things…
Each one of her minor movements has been monumental to us. It’s amazing and breathtaking every time.
It's the joy of simple things. Each one of her minor movements has been monumental to us. It's amazing and breathtaking every time.